文献速递消化系统肿瘤

重复检测mutKRAS ctDNA可早期预测晚期胰腺癌化疗反应并监测疗效

Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer.
PubMed 文献 · Ann Oncol · 2018-01-01

该研究纳入54例接受吉西他滨为基础化疗的晚期胰腺癌患者,连续采集284份血浆样本,用BEAMing技术检测mutKRAS ctDNA及CA19-9、CEA、CYFRA21-1。结果显示mutKRAS ctDNA可高敏高特异反映组织KRAS状态,其动力学变化较蛋白标志物更早预测疗效,随访中检测疾病进展的敏感性83%、特异性100%。

要点

  • mutKRAS ctDNA检测组织KRAS突变敏感性75%、特异性100%。
  • 治疗中mutKRAS ctDNA下降早于蛋白标志物提示治疗反应。
  • 随访中mutKRAS ctDNA检测进展敏感性83%、特异性100%。

核心结论

  • mutKRAS ctDNA动力学是晚期胰腺癌化疗早期反应预测和疗效监测的有力且高度特异的工具。

研究设计与样本

  • 研究纳入54例接受吉西他滨为基础化疗的晚期胰腺癌患者,连续采集284份血浆样本。
  • 采用BEAMing技术检测mutKRAS ctDNA及CA19-9、CEA、CYFRA21-1,并与影像学反应、无进展生存和总生存相关分析。

主要发现

  • 67%(36/54)的晚期胰腺癌患者可检测到mutKRAS ctDNA,其反映组织KRAS突变状态的敏感性75%、特异性100%。
  • 一线化疗前存在mutKRAS ctDNA及CA19-9、CEA、CYFRA21-1较高水平均与总生存不良显著相关。
  • 治疗期间mutKRAS ctDNA水平变化较蛋白标志物更迅速明显,其下降是治疗反应的早期指标,而CA19-9、CEA、CYFRA21-1动力学与化疗反应无显著相关。
  • 随访中重复检测mutKRAS ctDNA检测疾病进展优于蛋白标志物,敏感性83%、特异性100%。

临床怎么用

  • 对晚期胰腺癌患者可考虑连续检测mutKRAS ctDNA以早期预测化疗反应。
  • 随访中mutKRAS ctDNA动力学可用于监测疾病进展。

局限性

  • 研究为小样本探索性分析(54例),需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The presence of mutated KRAS (mutKRAS ctDNA) in plasma samples has been consistently shown to be a negative prognostic indicator in pancreatic cancer (PC). Only small pilot studies have evaluated the value of serial mutKRAS ctDNA-measurements in PC. PATIENTS AND METHODS: The aim of the present study was to explore the potential of repeated mutKRAS ctDNA measurements for response prediction and therapy monitoring in advanced PC patients. We used the BEAMing technology to determine levels of mutKRAS ctDNA, CA 19-9, CEA and CYFRA 21-1 in 284 plasma samples of 54 patients with advanced PC receiving gemcitabine-based chemotherapy. Absolute levels and kinetics of mutKRAS ctDNA, CA 19-9, CEA and CYFRA 21-1 were correlated to radiological response, progression-free and overall survival. RESULTS: mutKRAS ctDNA was present in a majority of advanced PC patients (n = 36/54, 67%) and indicated tissue KRAS mutation status with a high sensitivity (75%) and specificity (100%). The presence of mutKRAS ctDNA, as well as higher levels of CA 19-9, CEA and CYFRA 21-1 before initiation of the first-line chemotherapy, was significantly correlated to an adverse overall survival. During therapy, changes in mutKRAS ctDNA levels were more rapid and pronounced than changes in protein-based tumor markers. A decrease in mutKRAS ctDNA levels during therapy was an early indicator of response to therapy, while there was no significant correlation between kinetics of CA 19-9, CEA or CYFRA 21-1 and response to chemotherapy during the first four weeks of treatment. Repeated mutKRAS ctDNA measurements during follow-up appeared to be superior to protein-based tumor markers in detecting progressive disease (sensitivity: 83%, specificity: 100%). CONCLUSION: mutKRAS ctDNA kinetics appear to be a powerful and highly specific tool in early response prediction and therapy monitoring of advanced PC patients receiving chemotherapy.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Kruger S, Heinemann V, Ross C, et al. Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer. Ann Oncol. 2018. PMID: 30346475. doi:10.1093/annonc/mdy417

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。